Institution
Université libre de Bruxelles
Education•Brussels, Belgium•
About: Université libre de Bruxelles is a education organization based out in Brussels, Belgium. It is known for research contribution in the topics: Population & Breast cancer. The organization has 24974 authors who have published 56969 publications receiving 2084303 citations. The organization is also known as: ULB.
Topics: Population, Breast cancer, Large Hadron Collider, Receptor, Cancer
Papers published on a yearly basis
Papers
More filters
••
University of Melbourne1, Université libre de Bruxelles2, Katholieke Universiteit Leuven3, St. Vincent's Health System4, La Trobe University5, Royal Melbourne Hospital6, Netherlands Cancer Institute7, University of California, San Diego8, Vanderbilt University9, Peter MacCallum Cancer Centre10, University of Paris11, French Institute of Health and Medical Research12, Medical University of Vienna13, Cornell University14, University of Texas MD Anderson Cancer Center15, Mayo Clinic16, Royal Brisbane and Women's Hospital17, University of Queensland18, Harvard University19, Novartis20, Indiana University – Purdue University Indianapolis21, Fred Hutchinson Cancer Research Center22, University of Milan23, University of Auvergne24, Kansai Medical University25, Yeshiva University26, Yonsei University27, Brown University28, Rhode Island Hospital29, Curie Institute30, Charité31, Yale University32, University of British Columbia33, University of Victoria34, Garvan Institute of Medical Research35, Université Paris-Saclay36, Autonomous University of Madrid37, University of Ottawa38, National Institutes of Health39, New York University40, University of Adelaide41, Stanford University42, Anschutz Medical Campus43, University of Padua44, European Organisation for Research and Treatment of Cancer45, Medical University of Graz46, Hoffmann-La Roche47, Genentech48, MedImmune49, Merck & Co.50, Memorial Sloan Kettering Cancer Center51
TL;DR: In this paper, a standardized methodology to assess tumor-infiltrating lymphocytes (TILs) in solid tumors on hematoxylin and eosin sections, in both primary and metastatic settings, was proposed.
Abstract: Assessment of tumor-infiltrating lymphocytes (TILs) in histopathologic specimens can provide important prognostic information in diverse solid tumor types, and may also be of value in predicting response to treatments. However, implementation as a routine clinical biomarker has not yet been achieved. As successful use of immune checkpoint inhibitors and other forms of immunotherapy become a clinical reality, the need for widely applicable, accessible, and reliable immunooncology biomarkers is clear. In part 1 of this review we briefly discuss the host immune response to tumors and different approaches to TIL assessment. We propose a standardized methodology to assess TILs in solid tumors on hematoxylin and eosin sections, in both primary and metastatic settings, based on the International Immuno-Oncology Biomarker Working Group guidelines for TIL assessment in invasive breast carcinoma. A review of the literature regarding the value of TIL assessment in different solid tumor types follows in part 2. The method we propose is reproducible, affordable, easily applied, and has demonstrated prognostic and predictive significance in invasive breast carcinoma. This standardized methodology may be used as a reference against which other methods are compared, and should be evaluated for clinical validity and utility. Standardization of TIL assessment will help to improve consistency and reproducibility in this field, enrich both the quality and quantity of comparable evidence, and help to thoroughly evaluate the utility of TILs assessment in this era of immunotherapy.
415 citations
••
TL;DR: The multiple facets of r IL-10 in experimental immunopathology indicate that the success of clinical trials with rIL-10 will depend both on the appropriate selection of the patient populations to be treated and on the early detection of possible adverse effects.
Abstract: Interleukin-10 (IL-10) is a potent anti-inflammatory and immunosuppressive cytokine secreted by several cell types. Most anti-inflammatory effects of IL-10 are caused by its ability to deactivate macrophages and monocytes, whereas its immunosuppressive properties are due to functional inhibition of both antigen-presenting cells and T cells. On the other hand, IL-10 also exerts immunostimulatory effects, especially on B cells, CD8+ cytotoxic T cells and natural killer cells. In vivo administration of recombinant IL-10 (rIL-10) efficiently prevents experimental septic shock induced by endotoxin, staphylococcal superantigen or cecal ligation and puncture, as well as experimental autoimmune diseases mediated by T helper type 1 (T(H)1) cells and other inflammatory disorders. rIL-10 exerts paradoxical effects in cancer models, where it promotes tumour rejection, probably due to its stimulatory properties on cytotoxic cells. On the other hand, rIL-10 increases the severity of experimental infections caused by fungi or bacteria, and enhances systemic autoimmune features in mice with spontaneous lupus syndrome. Although the therapeutic potential of rIL-10 in human diseases seems promising, the multiple facets of rIL-10 in experimental immunopathology indicate that the success of clinical trials with rIL-10 will depend both on the appropriate selection of the patient populations to be treated and on the early detection of possible adverse effects.
415 citations
••
TL;DR: Because no etiologic therapy is available for Duchenne muscular dystrophy, a better understanding of the primary and downstream mechanisms could prove useful for producing new adjuvant treatments.
413 citations
••
TL;DR: A formal "small tension" expansion of D=11 supergravity near a spacelike singularity is shown to be equivalent, at least up to 30th order in height, to a null geodesic motion in the infinite-dimensional coset space E(10)/K(E 10), where K(E10) is the maximal compact subgroup of the hyperbolic Kac-Moody group E10(R).
Abstract: A formal ``small tension'' expansion of $D=11$ supergravity near a spacelike singularity is shown to be equivalent, at least up to 30th order in height, to a null geodesic motion in the infinite-dimensional coset space ${E}_{10}/K({E}_{10})$, where $K({E}_{10})$ is the maximal compact subgroup of the hyperbolic Kac-Moody group ${E}_{10}(\mathbb{R})$. For the proof we make use of a novel decomposition of ${E}_{10}$ into irreducible representations of its $\mathrm{S}\mathrm{L}(10,\mathbb{R})$ subgroup. We explicitly show how to identify the first four rungs of the ${E}_{10}$ coset fields with the values of geometric quantities constructed from $D=11$ supergravity fields and their spatial gradients taken at some comoving spatial point.
413 citations
••
TL;DR: An observational study conducted in ICUs around the world to evaluate how physicians conduct FCs in terms of type, volume, and rate of given fluid and to compare the proportion of patients receiving further fluid administration based on the response to the FC.
Abstract: Background
Fluid challenges (FCs) are one of the most commonly used therapies in critically ill patients and represent the cornerstone of hemodynamic management in intensive care units. There are clear benefits and harms from fluid therapy. Limited data on the indication, type, amount and rate of an FC in critically ill patients exist in the literature. The primary aim was to evaluate how physicians conduct FCs in terms of type, volume, and rate of given fluid; the secondary aim was to evaluate variables used to trigger an FC and to compare the proportion of patients receiving further fluid administration based on the response to the FC.
413 citations
Authors
Showing all 25206 results
Name | H-index | Papers | Citations |
---|---|---|---|
Karl J. Friston | 217 | 1267 | 217169 |
Yi Chen | 217 | 4342 | 293080 |
David Miller | 203 | 2573 | 204840 |
Jing Wang | 184 | 4046 | 202769 |
H. S. Chen | 179 | 2401 | 178529 |
Jie Zhang | 178 | 4857 | 221720 |
Jasvinder A. Singh | 176 | 2382 | 223370 |
D. M. Strom | 176 | 3167 | 194314 |
J. N. Butler | 172 | 2525 | 175561 |
Andrea Bocci | 172 | 2402 | 176461 |
Bradley Cox | 169 | 2150 | 156200 |
Marc Weber | 167 | 2716 | 153502 |
Hongfang Liu | 166 | 2356 | 156290 |
Guenakh Mitselmakher | 165 | 1951 | 164435 |
Yang Yang | 164 | 2704 | 144071 |